Tirzepatide for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Tirzepatide Weight Loss Efficacy in Obesity and Overweight
Multiple large clinical trials and meta-analyses show that tirzepatide, a dual GIP and GLP-1 receptor agonist, leads to significant and sustained weight loss in adults with obesity or overweight. Across studies, weekly doses of tirzepatide (5 mg, 10 mg, and 15 mg) resulted in average weight reductions ranging from about 7.7 kg to 20.9% of baseline body weight over 72 weeks, which is much greater than placebo and superior to other weight loss medications like semaglutide and liraglutide in head-to-head comparisons 1345+3 MORE. The proportion of participants achieving at least 5%, 10%, and 15% weight loss was also much higher with tirzepatide, with up to 91% of patients losing at least 5% of their body weight and over half losing 20% or more at higher doses 3467+1 MORE.
Tirzepatide Compared to Other Weight Loss Therapies
Tirzepatide consistently outperformed placebo, GLP-1 receptor agonists (such as semaglutide), and insulin in reducing body weight, BMI, and waist circumference 4567+1 MORE. In direct comparisons, tirzepatide led to greater weight loss than semaglutide and liraglutide, and the effect was dose-dependent, with higher doses producing more pronounced results 4579. These findings suggest tirzepatide may be the most effective medication currently available for weight loss in people with obesity or overweight, including those with type 2 diabetes 4578+1 MORE.
Cardiometabolic Benefits Beyond Weight Loss
In addition to weight reduction, tirzepatide improved several cardiometabolic risk factors, including reductions in waist circumference, blood pressure, fat mass, and improvements in insulin sensitivity and lipid profiles 3678. These changes are important because they may lower the risk of obesity-related complications such as cardiovascular disease and type 2 diabetes 368.
Safety and Adverse Events of Tirzepatide
The most common side effects of tirzepatide are gastrointestinal, including nausea, vomiting, diarrhea, and decreased appetite. These events are generally mild to moderate and occur mainly during the dose-escalation period 1345+3 MORE. While the overall rate of adverse events is higher with tirzepatide compared to placebo, the risk of serious adverse events and hypoglycemia is low and similar to or lower than with other weight loss drugs or insulin 57. The safety profile of tirzepatide is considered acceptable, but monitoring for gastrointestinal symptoms is recommended 157.
Tirzepatide After Lifestyle Intervention
Tirzepatide also provides substantial additional weight loss in people who have already achieved weight reduction through intensive lifestyle changes. In one study, participants who lost at least 5% of their body weight with diet and exercise and then received tirzepatide lost an additional 18.4% of their body weight, compared to just 2.5% with placebo . This suggests tirzepatide can help maintain and further enhance weight loss after lifestyle interventions .
Conclusion
Tirzepatide is a highly effective medication for weight loss in adults with obesity or overweight, leading to greater and more sustained weight reduction than other available therapies. It also improves several cardiometabolic risk factors. The main side effects are gastrointestinal and usually mild to moderate. Tirzepatide represents a promising new option for weight management, both as a primary therapy and as an adjunct to lifestyle interventions 1345+5 MORE.
Sources and full results
Most relevant research papers on this topic